Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Qiagen ( (QGEN) ) just unveiled an update.
QIAGEN has announced a plan to return approximately $300 million to shareholders through a synthetic share repurchase, combining direct capital repayment with a reverse stock split to enhance earnings per share. This initiative, following a similar $300 million return in early 2024, is part of QIAGEN’s commitment to return at least $1 billion to shareholders by 2028, aiming to efficiently enhance shareholder value while maintaining a strong investment-grade profile.
More about Qiagen
QIAGEN N.V. is a Netherlands-based holding company that is a leading global provider of Sample to Insight solutions, enabling customers to gain valuable molecular insights from samples. The company’s technologies include sample processing, assay technologies for biomolecule analysis, bioinformatics software, and automation solutions. QIAGEN serves over 500,000 customers worldwide in the fields of Molecular Diagnostics and Life Sciences, employing more than 5,800 people across 35 locations globally.
YTD Price Performance: 0.36%
Average Trading Volume: 855,362
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $9.91B
See more data about QGEN stock on TipRanks’ Stock Analysis page.
